von MoosRStrasserFGillessenS, et al.Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer2008; 16: 1105–1115.
2.
HenryDHCostaLGoldwasserF, et al.Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol2011; 29: 1125–1132.
3.
HenryDVadhan-RajSHirshV, et al.Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer2014; 22: 679–687.
4.
FizaziKCarducciMSmithM, et al.Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet2011; 377: 813–822.
5.
SmithMRSaadFColemanR, et al.Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet2012; 379: 39–46.
6.
LiptonAFizaziKStopeckAT, et al.Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer2012; 48: 3082–3092.
7.
LiptonAFizaziKStopeckAT, et al.Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer2016; 53: 75–83.
8.
RajeNTerposEWillenbacherW, et al.Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol2018; 19: 370–381.
9.
StopeckATLiptonABodyJJ, et al.Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol2010; 28: 5132–5139.
10.
ChernyNISullivanRDafniU, et al.A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol2015; 26: 1547–1573.
11.
GiulianiJBonettiA. Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018. Eur J Cancer2018; 104: 233–235.
12.
OlchanskiNZhongYCohenJT, et al.The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. Expert Rev Pharmacoecon Outcomes Res2015; 15: 931–940.
13.
CohnDEKimKHResnickKE, et al.At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol2011; 29: 1247–1251.
14.
McKiernanJMDeleaTELissM, et al.Impact of skeletal complications on total medical care costs in prostate cancer patients with bone metastases. J Clin Oncol2004; 22: 6057. ASCO Annual Meeting Proceedings.
15.
BarlevASongXIvanovB, et al.Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm2010; 16: 693–702.
16.
AzimiNAWelchHG. The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med1998; 13: 664–669.
17.
HowardLE, et al.Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?Prostatic Cancer Prostatic Dis2016; 19: 380–384.
18.
UlasA, et al.Risk factor for skeletal-related events (SREs) and factors affectin SRE-free survival for non small-cell lung cancer patients with bone metastases. Tumor Biol2016; 37: 1131–1140.
19.
GiulianiJBonettiA. Financial toxicity and non-small cell lung cancer treatment: the optimization in the choice of immune check point inhibitors. Anticancer Res2019; 39: 3961–3965.
20.
GiulianiJBonettiA. Immunotherapy in first-line for advanced non-small cell lung cancer: a cost-effective choice?Recenti Prog Med2019; 110: 138–143.
21.
GiulianiJBonettiA. Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level. Oral Oncol2019; 97: 143–145.
22.
GiulianiJBonettiA. Nivolumab in second-line treatment for advanced non-small-cell lung cancer with squamous-cell histology: a perspective based on pharmacologic costs. Clin Lung Cancer2017; 18: e363–e365.
23.
GiulianiJBonettiA. Nivolumab is a cost-effective second-line treatment for metastatic renal-cell carcinoma. Clin Genitourin Cancer2018; 16: e557–e562.
